A phase II trial of weekly 1-hour paclitaxel as second-line therapy for endometrial and cervical cancer

International Journal of Clinical Oncology

Volumn 13, Issue 1, 2008, Pages 62-65

  Homesley, Howard D ^a   Meltzer, Nathan P ^a   Nieves, Lucybeth ^a   Vaccarello, Luis ^b   Lowendowski, George S ^b   Elbendary, Al A ^c  

^a EAST CAROLINA UNIVERSITY   (United States)

^b Gynecologic Oncology and Pelvic Surgery   (United States)

^c St Louis Oncology Associates   (United States)

Author keywords

Cervical cancer; Endometrial cancer; Paclitaxel

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; PACLITAXEL;

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DISSEMINATED CANCER; DRUG EFFICACY; ENDOMETRIUM CANCER; FEMALE; HUMAN; LABORATORY TEST; MONOTHERAPY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, SQUAMOUS CELL; DRUG ADMINISTRATION SCHEDULE; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; PACLITAXEL; UTERINE CERVICAL NEOPLASMS;

EID: 40149090469     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-007-0731-5     Document Type: Article

References (28)

1. 2 every 4 weeks in endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 98:294-298
2. Bonomi P, Blessing JA, Stehman FB, et al. (1985) Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 3:1079-1085
3. Lhomme C, Vermorken JB, Mickiewicz E, et al. (2000) Phase II trial of vinorelbine in patients with advanced and/or recurrent cervical carcinoma: an EORTC Gynaecological Cancer Cooperative Group Study. Eur J Cancer 36:194-199
4. Schilder RJ, Blessing JA, Morgan M, et al. (2000) Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 76:204-207
5. Ota S, Sugiyama T, Ushijima K, et al. (2001) Remission of metastatic cervical adenocarcinoma with weekly paclitaxel. Int J Gynecol Cancer 11:167-168
6. Moore DH, Blessing JA, McQuellon RP, et al. (2004) Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 22:3113-3119
7. Terauchi F, Nagashima T, Kobayashi Y, et al. (2005) A pilot study of weekly paclitaxel administration for patients with relapsed cervical cancer after heavy medication. Gan to Kagaku Ryoho (Japanese Journal of Cancer & Chemotherapy) 32:641-644
8. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al. (1994) European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high dose versus low dose and long versus short infusion. J Clin Oncol 12:2654-2666
9. Greco FA, Hainsworth JD (1994) Paclitaxel (Taxol): phase I/II trial comparing 1 hour infusion schedules. Semin Oncol 21:3-8
10. Schiller JH, Storer B, Tutsch K, et al. (1994) Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol 12:241-248
11. Balat O, Kudelka AP, Tunca JC, et al. (1996) Prolonged stabilization of progressive platinum-refractory ovarian cancer with paclitaxel: brief report. Eur J Gynecol Oncol 17:264-266
12. Tsavaris N, Polyzos A, Kosmas C, et al. (1997) A feasibility study of 1 h paclitaxel infusion in patients with solid tumors. Cancer Chemo Pharm Cancer Chemotherapy & Pharmacology 40: 353-357
13. Seidman AD, Hudis CA, Albanel J, et al. (1998) Dose-dense therapy with weekly 1-h paclitaxel infusion in the treatment of metastatic breast cancer. J Clin Oncol 16:3353-3361
14. Klaassen U, Wilke H, Strumberg D, et al. (1996) Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer. Eur J Cancer 32A:547-549
15. Loffler TM, Freund W, Lipke J, et al. (1996) Schedule-and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: results of a phase I/II trial. Semin Oncol 23:32-34
16. Abu-Rustum N, Aghajanian C, Barakat RR, et al. (1997) Salvage weekly paclitaxel in recurrent ovarian cancer. Semin Oncol 24:62-67
17. Fennelly D, Aghajanian C, Shapiro F, et al. (1997) Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 15:187-192
18. Perez EA, Vogel CL, Irwin DH, et al. (2001) Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 19:4216-4223
19. Markman M, Hall J, Spitz D, et al. (2002) Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol 20:2365-2369
20. Rosenberg P, Andersson H, Boman K, et al. (2002) Randomized trial of single agent paclitaxel given weekly versus every 3 weeks and with per oral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncol 41:418-424
21. Vaughn DJ, Broome CM, Hussain M, et al. (2002) Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 20:937-940
22. Boruta DM 2nd, Fowler WC Jr, Gehrig PA, et al. (2003) Weekly paclitaxel infusion as salvage therapy in ovarian cancer. Cancer Invest 21:675-681
23. Markman M, Fowler J (2004) Activity of weekly paclitaxel in patients with advanced endometrial cancer previously treated with both a platinum agent and paclitaxel. Gynecol Oncol 92:180-182
24. Akizuki S, Katsumata N, Yamanaka Y, et al. (2005) Weekly paclitaxel in patients with CAP-resistant advanced or recurrent endometrial carcinoma: a series of four patients. Int J Clin Oncol 10:272-275
25. Ball HG, Blessing JA, Lentz SS, et al. (1996) A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 62:278-281
26. Woo HL, Swenerton KD, Hoskins PH (1996) Taxol is active in platinum-resistant endometrial adenocarcinoma. Am J Clin Oncol 19:290-291
27. Lissoni A, Zanetta G, Losa G, et al. (1996) Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer. Ann Oncol 7:861-863
28. Nishio S, Ota S, Sugiyama T, et al. (2003) Weekly 1-h paclitaxel infusion in patients with recurrent endometrial cancer: a preliminary study. In J Clinical Oncol 8:45-48